IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación (Site 0851)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Lung cancer

Running trials

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Toll Free Number